Fil d'Ariane

null Scott Owen, M.D.

Chercheur, IR-CUSM

Programme de recherche sur le cancer

Professeur adjoint, Département d'oncologie Gerald Bronfman, Faculté de médecine et des sciences de la santé, Université McGill

Département de médecine spécialisée, Division d'oncologie médicale, CUSM

 

Mots-clés

cancer du poumon • cancer du cerveau • gliomes

Aire de recherche

Mes recherches portent sur les essais cliniques visant à améliorer la survie des patients atteints d'un cancer du poumon ou du cerveau.

Publications choisies

Cliquez sur Pubmed pour voir la liste de mes publications

  • Schmid, Severin et al. “Neoadjuvant Prehabilitation Therapy for Locally Advanced Non-Small-Cell Lung Cancer: Optimizing Outcomes Throughout the Trajectory of Care.” Clinical lung cancer vol. 23,7 (2022): 593-599. DOI: 10.1016/j.cllc.2022.05.004. PMID: 35705449.

  • Paz-Ares, Luis G et al. “Sacituzumab Govitecan Versus Docetaxel for Previously Treated Advanced or Metastatic Non-Small Cell Lung Cancer: The Randomized, Open-Label Phase III EVOKE-01 Study.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology vol. 42,24 (2024): 2860-2872. DOI: 10.1200/JCO.24.00733. PMID: 38843511.

  • Passaro, A et al. “Amivantamab plus chemotherapy with and without lazertinib in EGFR-mutant advanced NSCLC after disease progression on osimertinib: primary results from the phase III MARIPOSA-2 study.” Annals of oncology : official journal of the European Society for Medical Oncology vol. 35,1 (2024): 77-90. DOI: 10.1016/j.annonc.2023.10.117. PMID: 37879444.

  • Felip, E et al. “Amivantamab plus lazertinib versus osimertinib in first-line EGFR-mutant advanced non-small-cell lung cancer with biomarkers of high-risk disease: a secondary analysis from MARIPOSA.” Annals of oncology : official journal of the European Society for Medical Oncology vol. 35,9 (2024): 805-816. DOI: 10.1016/j.annonc.2024.05.541. PMID: 38942080.